Journal of Antimicrobial Chemotherapy (2002) 49, 1044-1046
© 2002 The British Society for Antimicrobial Chemotherapy
Correspondence |
Hepatitis B virus surface antigen mutants persist in chronic carriers receiving lamivudine therapy in Singapore
1Department of Clinical Research and 2Ransome Research Laboratory, Singapore General Hospital, Singapore 169608, Republic of Singapore
Sir,
Lamivudine, the negative enantiomer of 2'-dideoxy-3'-thiacytidine, is a reverse transcriptase inhibitor for both human immunodeficiency virus (HIV) and human hepatitis B virus (HBV). Its application has so far resulted in a reduction of serum HBV DNA in chronic carriers and also improved liver function.1 However, prolonged lamivudine therapy has resulted in mutations in the Tyr-Met-Asp-Asp (YMDD) motif of the HBV DNA polymerase.2 Although the HBV DNA polymerase and viral surface antigen (HBsAg) are translated from the same coding region, albeit different reading frames,
Acknowledgements
Footnotes
References